Estrella Immunopharma (Estrella Immunopharma) Current Accrued Expense : $0.09 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Current Accrued Expense?

Estrella Immunopharma's Current Accrued Expense for the quarter that ended in Mar. 2024 was $0.09 Mil.

Estrella Immunopharma's quarterly Current Accrued Expense declined from Sep. 2023 ($2.13 Mil) to Dec. 2023 ($0.25 Mil) and declined from Dec. 2023 ($0.25 Mil) to Mar. 2024 ($0.09 Mil).

Estrella Immunopharma Current Accrued Expense Historical Data

The historical data trend for Estrella Immunopharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Current Accrued Expense Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Current Accrued Expense

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial					-	-	2.13	0.25	0.09

Estrella Immunopharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Estrella Immunopharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines